Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Lymphangioleiomyomatosis × nintedanib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 18 Ovarian Neoplasms 8 Neoplasms 7 Colorectal Neoplasms 5 Recurrence 4 Small Cell Lung Carcinoma 3 Prostatic Neoplasms 3 Glioblastoma 3 Carcinoma, Hepatocellular 3 Breast Neoplasms 3 Uterine Cervical Neoplasms 2 Radiation Pneumonitis 2 Peritoneal Neoplasms 2 Mesothelioma, Malignant 2 Lung Neoplasms 2 Leukemia, Myeloid, Acute 2 Fallopian Tube Neoplasms 2 Carcinoma, Renal Cell 2 Thyroid Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Solid Tumors 1 Sarcoma 1 Rectal Neoplasms 1 Patients With Any Advanced Solid Tumors 1 Pancreatic Neoplasms 1 Ovarian Diseases 1 Oligodendroglioma 1 Neuroendocrine Tumors 1 Neoplasms by Site 1 Neoplasm Metastasis 1

Interventions

Sirolimus 10 Everolimus 6 Imatinib Mesylate 2 temsirolimus 1 saracatinib 1 nintedanib 1 carbon-11 acetate 1 Valproic Acid 1 Urination 1 Sugars 1 Simvastatin 1 Resveratrol 1 Respiratory Function Tests 1 Phlebotomy 1 Octreotide 1 Loratadine 1 Letrozole 1 Immunoglobulin G 1 Hydroxychloroquine 1 Glutamine 1 Genetic Testing 1 Doxycycline 1 Disulfides 1 Cetuximab 1 Celecoxib 1 Bevacizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03062943 2022-09-28

LAM

IRCCS Multimedica

Phase 2 Completed

Lymphangioleiomyomatosis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡